Skip to main content
OpenTrials
Completed

NCT Number: NCT07718880

Nephroprotective Effects of Fig (Ficus Carica L.) Leaf Supplementation

Diabetic nephropathy is the result of diabetes complications. Excessive blood glucose levels affect several organs which include liver, heart, and kidneys.The aim of this study is to use the nephroprotective and metabolic effects of fig (Ficus carica L.) leaf supplementation with a low glycemic index diet in grade-II chronic kidney disease patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabete Mellitus Chronic Disease Diabetes Complications Diabetes Mellitus Diabetic Nephropathies Diabetic Nephropathy Disease Attributes Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Kidney Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The University of Lahore

Lahore, Pakistan

About this study

A pre and post treatment study that evaluated 60 patients (35-65 years old) diagnosed with diabetes and stage 2 chronic kidney disease. Purposive sampling was used to include patients that fit the criteria. The 60 patients selected were randomly divided among two groups: control group and intervention group, each group with 30 patients. Control group patients were given green tea and intervention group patients were given fig leaf tea along with a low glycemic index diet. The tea for both groups was assigned to drink twice a day. The period of this research is 8 weeks. At four weeks , the participants were asked for their feedback. Pre- and post-results were assessed and monitored

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People within the age range of 35-65 years old adults (both genders)
  • Individuals diagnosed with Type 2 diabetes with an HbA1c level between 7-13%
  • Diabetics that consume oral hypoglycemic medication
  • Participants must have a BMI between 25kg/m2 and 39.9kg/m2

Exclusion criteria

  • Pregnant and lactating women
  • Individuals that use insulin therapy apart from medication
  • Severe complications like diabetic ketoacidosis
  • Individuals with highly restricted diets
  • Allergic to latex or figs.

Treatment and study plan

Control group

Dietary Supplement

Participants were guided to make Jasmine Green tea by boiling 200ml of water and add tea bag twice a day

Intervention Group

Dietary Supplement

Participants were advised to take Fig leaf tea (200ml/tea bag) twice a day for 8 weeks. Low glycemic index diet plan was also followed.

Primary outcomes

  1. Body Mass Index

    Time frame: 8 weeks

    Body mass index (BMI) is a universally utilized anthropometric screening tool that is used to assess a person's health by evaluating their obesity and nutritional status, applies for both males and females. For body mass index weight in kg and height in meters squared, were used to calculate changes in body size.

  2. Fasting blood glucose (FBG)

    Time frame: 8 weeks

    Fasting blood glucose (FBG) is a simple test that measures a person's blood sugar level after fasting for approximately 8-12 hours. This test determines the amount of glucose present on an empty stomach to understand the baseline of glucose levels. A glucometer is used to measure FBG. The unit for FBG is mg/dL. For this study the range to determine stage 2 diabetic kidney damage is approximately 120 - 300 mg/dL.

  3. Lipid profile

    Time frame: 8 weeks

    Lipid profile is a key blood-based biomarker that measures the amount of lipid present in the blood of a person. The key components of lipid profile we will use are triglycerides, total cholesterol, low density lipoprotein (LDL), and high density lipo-protein (HDL). These components are used to detect any unnecessary amount of lipids present in the blood for early detection of health issues. Triglycerides are the storage form of lipid. Total cholesterol is the overall amount of lipid components. LDL also known as "bad" cholesterol accumulates in blood causing problems in bloodstream. HDL also known as "good" cholesterol reduces amounts of LDL cholesterol in blood. The unit used is mg/dL (L. Wang et al., 2022). In this study the ranges used to determine stage 2 diabetic kidney damage are: triglycerides (150 - 290mg/dl), total cholesterol (160 - 300 mg/dl), LDL (130 - 190 mg/dl), and HDL (20 - 50 mg/dl).

  4. Renal function tests

    Time frame: 8 weeks

    Renal function tests (RFT) take place to evaluate the functionality of kidneys and if they properly filter waste. Blood and urine samples are taken, and serum creatinine and blood urea nitrogen (BUN) are tests that detect possible kidney damage or disease. For diabetics diagnosis of kidney damage as early as possible is essential for treatment (Gounden, Bhatt, & Jialal, 2024). In this study the ranges used to determine Stage 2 diabetic kidney damage are: serum creatinine (1.05 - 2.0 mg/dl), and blood urea nitrogen (20 - 46 mg/dl).

Sponsors and collaborators

Lead sponsor

University of Lahore

Other

Registry information

Official study title

Nephroprotective Effects of Fig (Ficus Carica L.) Leaf Supplementation in Grade II Chronic Kidney Disease

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jul 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.